FUNDING FOR CONTINUED DEVELOPMENT OF NEUROSTIMULATION DEVICE TO TREAT OBSTRUCTIVE SLEEP APNEA (OSA) HOUSTON, Texas, October 5, 2011 — Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced an initial investment of $4 million in ImThera Medical, Inc. (“ImThera”). Based in San Diego, California, ImThera is [...]

Visit ImThera Medical at ATS 2011 Conference, Booth #347 Sleep apnea neurostimulation company to present data at the American Thoracic Society 2011 Conference SAN DIEGO, CA, May 9, 2011 – ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a [...]

The aura6000TM is one of the smallest implantable and rechargeable stimulators in the market MOUNTAIN VIEW, Calif. — April 26, 2011 — Based on its recent analysis of the neurostimulation for sleep apnea market, Frost & Sullivan recognizes ImThera Medical, Inc. with the 2011 North American Frost & Sullivan Award for Technology Innovation for its [...]

SAN DIEGO, CA, May 17, 2011 –ImThera Medical, Inc. reported results from its European study of the aura6000TM neurostimulation device for the treatment of Obstructive Sleep Apnea (OSA) at the American Thoracic Society (ATS) 2011 Conference. Safety and efficacy outcomes of the Phase I (three-month data) protocol are positive and included results of the Phase [...]

Apnea Hypoponea Index (AHI) reduced by 73% and Oxygen Desaturation Index (ODI) improved by 77% SAN DIEGO, CA, September 21, 2010 – ImThera Medical, Inc. today announced interim results from its OSA European clinical study. For the study, ten patients have been surgically implanted with ImThera’s aura6000TM hypoglossal nerve neurostimulation device for treating Obstructive Sleep [...]

SAN DIEGO, CA, December 1, 2009 – ImThera Medical, Inc. today announced that two patients have been surgically implanted with ImThera’s aura6000TM neurostimulation device for treating tongue‐based Obstructive Sleep Apnea (OSA). Patients are being enrolled in ImThera’s pilot clinical investigation in Belgium with the first results expected to be published in the first half of [...]

Visit ImThera Medical at AAO‐HNS, booth #1153 SAN DIEGO, CA., October 5, 2009 – Today, at the American Academy of Otolaryngology‐Head and Neck Surgery annual meeting, ImThera Medical, Inc. unveiled its new product, the aura6000TM neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA). More than 800,000 patients in the US are annually diagnosed [...]

Also receives ISO 13485 certification San Diego, CA., – September 29, 2009 – ImThera Medical, Inc. has received Ethics Committee clearance to begin human clinical trials in Belgium. The trials will include ImThera’s Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy to treat Obstructive Sleep Apnea (OSA). Along with the clinical trial approvals, ImThera has received ISO [...]

Surgical treatment option for non‐compliant CPAP patients SAN DIEGO, CA., – September 23, 2009 – ImThera Medical, Inc. announced today that it has completed development of its Targeted Hypoglossal Neurostimulation (THN) system for Obstructive Sleep Apnea (OSA). More than 800,000 patients in the US are annually diagnosed with OSA. While Continuous Positive Airway Pressure (CPAP) [...]